Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
TPG plans to grow the business while Actavis aims to focus on Global Supply Chain Network
February 13, 2015
By: Kristin Brooks
Managing Editor, Contract Pharma
Actavis plc and TPG, a global private investment firm, have entered a definitive agreement under which Actavis will divest its Aptalis Pharmaceutical Technologies (Pharmatech) business, which operates within Actavis’ subsidiary in the U.S., Canada and Europe. Financial terms were not disclosed. Pharmatech provides R&D and manufacturing services, with specialized capabilities in taste-masking and customized drug release and supports projects from formulation through scale-up and commercial-scale manufacturing. TPG intends to use Pharmatech as a platform to enter into new partnerships and make additional acquisitions to grow the business. TPG’s healthcare practice has invested approximately $6 billion in equity since 2007. John Fraher, current president of Aptalis Pharmaceutical Technologies, will become chief executive officer of the new standalone company, and will be joined by others from his management team. The business will continue to operate R&D and manufacturing facilities in North America and Europe. “Our decision to divest the Pharmatech business is consistent with our strategic commitment to build leadership positions in our core areas of strength,” said Robert Stewart, chief operating officer of Actavis. “It will enable our Global Operations team to sharpen their focus on supporting our existing global supply chain, and on preparing for the expansion of our manufacturing network with the addition of the Allergan facilities following the close of the acquisition later this year. The Pharmatech team has done an exceptional job in meeting its objectives, and I would like to thank them for the tremendous work they have done for Actavis.” According to Mr. Stewart, the decision to divest Pharmatech will have no impact on investing in and developing the Medis third-party business. “We’re excited to renew our partnership with TPG, and believe the firm’s experience in the pharma industry, combined with their past successes in establishing market-leaders from carve-outs, positions us well to build a new, successful platform,” said Mr. Fraher, president of Aptalis Pharmaceutical Technologies. The transaction, subject to customary closing conditions and regulatory approvals, is expected to close by mid-2015.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !